Disruption of Cell Signaling Pathways in Cancer: Prognostic and Treatment Perspectives
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 114
Special Issue Editors
Interests: gene expression; cancer; VEGF; HIPPO pathway; HH pathway; qPCR
Interests: tumor pathology—characterization of the pathologic background of tumors and tumor microenvironment, from microscopic morphology to molecular specificity, by highlighting the cellular and molecular features in tumor progression, as well as the cellular communication and interrelations between malignant and host tissues; correlation between the clinical profile and the pathological and molecular features, offering a perspective for a personalized approach of therapy; development of automated quantitative analysis in the microscopic morphologic diagnosis, through the application of the fundamental concepts from digital image processing and the exploitation of the software resources; renal pathology—assessment of fine needle biopsy, in native and transplanted kidney
Special Issue Information
Dear Colleagues,
Cancer is a genetic disease characterized by impaired cell function, uncontrolled cell growth and cell division regardless of environmental signals.
Genetic mutations in cancer cells imply the biosynthesis of RNA or proteins with impaired structures and functions, which leads to disruptions in intracellular signaling pathways. Thanks to the use of both modern and traditional research techniques, at least several thousand proteins are now known whose dysfunction is associated with the cancer process. This translates directly or indirectly into the disruption, positive or negative, of the metabolic, signaling, proliferation and other pathways.
Most types of cancer, depending on their cellular/tissue origin, are characterized by a unique pattern of disruption of cellular pathways. On the one hand, this allows for a prognostic assessment of the patient, allows for the establishment of a treatment algorithm and, at the same time, enables the creation of modern drugs that block elements of the overactive pathway. The search for modern therapies is also important due to the increasingly frequent reports of cancer cells becoming resistant to chemotherapy drugs.
In this special supplement in the renowned journal Cancers, we are interested in obtaining the latest knowledge regarding the analysis of pathway disorders in cancers in the hope of creating modern drugs and improved prognoses for patients
Dr. Piotr M. Wierzbicki
Prof. Dr. Irina Draga-Caruntu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oncogenes
- tumor suppressor genes
- signaling pathways
- targeted therapies
- outcome
- prognostic factor
- cancer resistance
